TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28901935

Group type: EXPERIMENTAL
Intervention: Duodenum-preserving pancreatic head resection (DPPHR)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Partial pancreatoduodenectomy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: DPPHR
Number of subjects: 250
Study: 25851895

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/q12h for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 40
Study: 24201304

Group type: EXPERIMENTAL
Intervention: New Year recruitment period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Summer recruitment period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fall recruitment period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New Year participants
Number of subjects: 0
Study: 21702706

Group type: EXPERIMENTAL
Intervention: Family involvement in care (FIC) intervention
Number of subjects: 116
Study: 18063345

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 200
Study: 16244099

Group type: EXPERIMENTAL
Intervention: Educational intervention (essay, lecture, video, group discussions, self-test, instructions on BSEs)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control condition (nutrition and exercise focus)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 172
Study: 12584036

Group type: EXPERIMENTAL
Intervention: iv pamidronate 120 mg for Group I, 180 mg for Group II, 240 mg for Group III
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: iv pamidronate
Number of subjects: 68
Study: 10874063

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for six weeks
Number of subjects: 854

Group type: COMPARATOR
Intervention: Oral anticoagulants for six months
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Overall incidence of cancer
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Standardized incidence ratio for newly diagnosed cancer
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Urogenital cancers
Number of subjects: 854
Study: 9086359

Group type: EXPERIMENTAL
Intervention: Riluzole (antiglutamate agent)
Number of subjects: 0
Study: 1577047

Group type: EXPERIMENTAL
Intervention: Adinazolam (5, 10, 15, 20 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NDMAD (10, 20, 30, 40 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2857036

Group type: EXPERIMENTAL
Intervention: Eproxindine
Number of subjects: 1

Group type: COMPARATOR
Intervention: Flupenthixol (depot injection)
Number of subjects: 1
Study: 30795753

Group type: EXPERIMENTAL
Intervention: Saffron (100 mg/d)
Number of subjects: 80
Study: 29966188

Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation (30 minutes per session, five times a week for 3 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional rehabilitation program (five times a week for 3 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation and conventional rehabilitation
Number of subjects: 35
Study: 26303968

Group type: EXPERIMENTAL
Intervention: Colgate Total(™) (CT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluor Protector Gel(™) (FPG)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (G1)
Number of subjects: 72
Study: 25379427

Group type: EXPERIMENTAL
Intervention: computer‐based facial affect training
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: targeted cognitive training on auditory‐verbal discrimination and working memory
Number of subjects: 57

Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 57
Study: 22286957

Group type: COMPARATOR
Intervention: Low-dose acute tryptophan depletion (LD-ATD) with no tryptophan (T−)
Number of subjects: 19
Study: 21638967

Group type: EXPERIMENTAL
Intervention: 1% Sodium hypochlorite (NaOCl) during instrumentation and a 15 minutes final irrigation with 2% iodine potassium iodide (IKI)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 1% Sodium hypochlorite (NaOCl) during instrumentation and a 5 minutes final irrigation with 2% iodine potassium iodide (IKI)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 1% Sodium hypochlorite (NaOCl) during instrumentation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sterile distilled water (control)
Number of subjects: 72
Study: 18325918

Group type: EXPERIMENTAL
Intervention: Ovarian function suppression (OFS) plus tamoxifen for 5 years
Number of subjects: 1317

Group type: EXPERIMENTAL
Intervention: Ovarian function suppression (OFS) plus exemestane for 5 years
Number of subjects: 1317

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 1317
Study: 15979652

Group type: EXPERIMENTAL
Intervention: NTX plus prazepam (one 10-mg tablet twice daily)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: NTX alone (one 50-mg tablet daily)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: NTX plus placebo (one 50-mg tablet daily plus one tablet twice daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No pharmacological treatment (control group)
Number of subjects: 56
Study: 11937475

Group type: EXPERIMENTAL
Intervention: Collagenase
Number of subjects: 135

Group type: COMPARATOR
Intervention: Fibrinolysin/deoxyribonuclease
Number of subjects: 135
Study: 11035992

Group type: EXPERIMENTAL
Intervention: Surgical treatments (hysterectomy, abdominal myomectomy, laparoscopic myomectomy, myolysis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsurgical treatments (uterine artery embolization, medical therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study: 8813271

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg) 0.4 g per kg body weight
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg)
Number of subjects: 30
Study: 1366259

Group type: COMPARATOR
Intervention: PROBE study design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical double-blind design
Number of subjects: 0
Study: 2931947

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: zimeldine
Number of subjects: 0
Study: 29546320

Group type: EXPERIMENTAL
Intervention: Resistance Training with Caloric Restriction (RT+CR; n=15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Resistance Training without Caloric Restriction (RT; n=16)
Number of subjects: 31
Study: 30221336

Group type: COMPARATOR
Intervention: Cepodoxime (100 mg twice per day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cepodoxime (100 mg) and aceclofenac (100 mg twice per day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 26807853

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 25
Study: 24351875

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) dietary advice
Number of subjects: 691

Group type: COMPARATOR
Intervention: Healthy Eating (HE) advice
Number of subjects: 691
Study: 23548570

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Gabapentin or Pregabalin
Number of subjects: 71
Study: 20164474

Group type: EXPERIMENTAL
Intervention: Coached group
Number of subjects: 215

Group type: COMPARATOR
Intervention: Not-coached group
Number of subjects: 215
Study: 18826865

Group type: EXPERIMENTAL
Intervention: Grape juice with diltiazem 180 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Orange juice with diltiazem 180 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water with diltiazem 180 mg
Number of subjects: 12
Study: 15805130

Group type: EXPERIMENTAL
Intervention: Intervention PCG/Ts received profiles with information on hospital admissions for accidental injury and their costs.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control PCG/Ts did not receive the intervention.
Number of subjects: 0
Study: 12576870

Group type: EXPERIMENTAL
Intervention: 10 mg. atrasentan
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: 2.5 mg. atrasentan
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 10588501

Group type: EXPERIMENTAL
Intervention: Oxidized regenerated cellulose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Absorbable gelatin sponge
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sterile gauze with external pressure (control)
Number of subjects: 30
Study: 8753111

Group type: EXPERIMENTAL
Intervention: 1800 micrograms/day of inhaled beclomethasone dipropionate (BDP) and bronchodilators
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1400 micrograms/day of inhaled beclomethasone dipropionate (BDP) and bronchodilators
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1800 micrograms/day of inhaled beclomethasone dipropionate (BDP)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1800 micrograms/day of inhaled beclomethasone dipropionate (BDP) and 1400 micrograms/day of BDP
Number of subjects: 26
Study: 29540424

Group type: EXPERIMENTAL
Intervention: Fixed dose of 1000 IU fIX prothrombin complex concentrate (PCC)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Variable dose of prothrombin complex concentrate (PCC) determined by patient-specific bodyweight and international normalised ratio
Number of subjects: 310
Study: 29071913

Group type: EXPERIMENTAL
Intervention: TEAS (2 Hz/100 Hz, 6-8 mA for LI 4-PC 6, 12-18 mA for ST 36-SP 6)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham-TEAS
Number of subjects: 58
Study: 24929888

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 400 mcg (1-2 doses, administered at least 3 hours before D&E)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Laminaria inserted the day before D&E
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 400 mcg
Number of subjects: 159

Group type: COMPARATOR
Intervention: Laminaria
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 159
Study: 22704926

Group type: EXPERIMENTAL
Intervention: HBV-ISS (0-4 weeks schedule)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HBV-ISS (0-8 weeks schedule)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 41
Study: 21029892

Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification (OZil)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Longitudinal phacoemulsification
Number of subjects: 148
Study: 17396041

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 162

Group type: COMPARATOR
Intervention: Amphotericin B (AMB)
Number of subjects: 162
Study: 15711571

Group type: EXPERIMENTAL
Intervention: BuCyVP (etoposide 60 mg/kg, busulfan 14 mg/kg, cyclophosphamide 120 mg/kg)
Number of subjects: 237

Group type: COMPARATOR
Intervention: BuCy2
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: BuCyVP
Number of subjects: 237
Study: 12422158

Group type: EXPERIMENTAL
Intervention: Resting periods of 15 minutes (Group 1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Resting periods of 30 minutes (Group 2)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Resting periods of 60 minutes (Group 3)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Resting periods of 120 minutes (Group 4)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group 1 (15 min rest)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group 2 (30 min rest)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group 3 (60 min rest)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Group 4 (120 min rest)
Number of subjects: 52
Study: 9609264

Group type: EXPERIMENTAL
Intervention: Ampicillin 500 mg intra-operatively
Number of subjects: 79

Group type: COMPARATOR
Intervention: No prophylactic antibiotics
Number of subjects: 79
Study: 8535492

Group type: EXPERIMENTAL
Intervention: Grinder exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chipping hammer exposure
Number of subjects: 0
Study: 2797635

Group type: EXPERIMENTAL
Intervention: Electronic fetal monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Periodic auscultation
Number of subjects: 0
Study: 30769

Group type: EXPERIMENTAL
Intervention: Lorazepam (3 mg per day, given b.i.d., 2 mg h.s. and 1 mg a.m. for 4 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31256870

Group type: EXPERIMENTAL
Intervention: Muscle Pump Activator (MPA) device
Number of subjects: 118

Group type: COMPARATOR
Intervention: TED + IPC
Number of subjects: 118
Study: 27808527

Group type: EXPERIMENTAL
Intervention: Dissonance-based eating disorder program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 47
Study: 25138265

Group type: EXPERIMENTAL
Intervention: 2,000 IU/day vitamin D3
Number of subjects: 26

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 26
Study: 23145957

Group type: EXPERIMENTAL
Intervention: Advise-coitus
Number of subjects: 1150
Study: 21478245

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-platelet-rich plasma (non-PRP)
Number of subjects: 51
Study: 19340512

Group type: EXPERIMENTAL
Intervention: NEM(R) 500 mg daily for 8 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 16966479

Group type: EXPERIMENTAL
Intervention: CT angiography
Number of subjects: 145
Study: 12718461

Group type: EXPERIMENTAL
Intervention: Clinical guidelines plus postal feedback on prescribing patterns for antibiotics
Number of subjects: 299

Group type: COMPARATOR
Intervention: Clinical guidelines only
Number of subjects: 299
Study: 10930561

Group type: EXPERIMENTAL
Intervention: Bright light (5000 lux) and caffeine (100 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bright light (5000 lux)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Caffeine (100 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Dim light placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bright light exposure
Number of subjects: 62
Study: 9382473

Group type: EXPERIMENTAL
Intervention: Macrophage-targeted glucocerebrosidase (Ceredase) infusions, dosage ranged from 120 to 480 U/kg of body weight/month
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Macrophage-targeted glucocerebrosidase (Ceredase) infusions
Number of subjects: 5
Study: 8266769

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms tds) by subcutaneous injection for 12 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo injections for 12 days
Number of subjects: 19
Study: 3534901

Group type: EXPERIMENTAL
Intervention: Pyritinol (200 mg, three times daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31152463

Group type: EXPERIMENTAL
Intervention: Telephone crisis counseling
Number of subjects: 234
Study: 29424030

Group type: EXPERIMENTAL
Intervention: TAC-ESD
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional-ESD
Number of subjects: 84
Study: 27408622

Group type: EXPERIMENTAL
Intervention: Unblinded patient self-reported outcome
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Blinded assessment of digital photographs
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Blinded outcome assessment at the site
Number of subjects: 240
Study: 24726004

Group type: EXPERIMENTAL
Intervention: Mechanochemical endovenous ablation (MOCA)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 460
Study: 23026303

Group type: EXPERIMENTAL
Intervention: Bunsimgi-eum (BSGE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (controlled medication)
Number of subjects: 0
Study: 20831455

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 18756848

Group type: EXPERIMENTAL
Intervention: Digital ridge pattern characteristics
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Gender comparison of digital ridge patterns
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Pattern Intensity Index
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Total finger ridge count and a-b ridge count
Number of subjects: 390
Study: 16230523

Group type: EXPERIMENTAL
Intervention: Omapatrilat (80 mg)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Enalapril (40 mg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 159
Study: 11850097

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (up to 300 mg bid)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 10726436

Group type: EXPERIMENTAL
Intervention: High intensity, short duration with glucose in milk (HS & GM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High intensity, short duration without glucose in milk (HS & NGM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low intensity, long duration with glucose in milk (LL & GM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low intensity, long duration without glucose in milk (LL & NGM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High intensity exercises
Number of subjects: 10
Study: 7785756

Group type: EXPERIMENTAL
Intervention: DAR Hygrobac HME
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gibeck Humid Vent 2P HME
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pall BB 22‐15 T HME
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pall BB 100 HME
Number of subjects: 25
Study: 2331550

Group type: EXPERIMENTAL
Intervention: Behavioural procedures
Number of subjects: 1
Study: 6999827

Group type: EXPERIMENTAL
Intervention: Ketocaine compresses (10% ethanol solution)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline compresses (placebo)
Number of subjects: 50
Study: 30895460

Group type: EXPERIMENTAL
Intervention: Aqua cycling (AC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Passive recovery (P)
Number of subjects: 20
Study: 28696415

Group type: EXPERIMENTAL
Intervention: Duloxetine (N = 186)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo (N = 205)
Number of subjects: 391
Study: 30228572

Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed pushing
Number of subjects: 0
Study: 26408290

Group type: EXPERIMENTAL
Intervention: Sexual assault risk reduction condition
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Alcohol use reduction condition
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Combined sexual assault risk and alcohol use reduction condition
Number of subjects: 207

Group type: COMPARATOR
Intervention: Full assessment only control condition
Number of subjects: 207

Group type: COMPARATOR
Intervention: Minimal assessment only condition
Number of subjects: 207
Study: 23212150

Group type: EXPERIMENTAL
Intervention: Prophylactic imatinib (arm A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: MRD-triggered imatinib (arm B)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 55
Study: 21606634

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Forced coughing
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control
Number of subjects: 114
Study: 19092037

Group type: EXPERIMENTAL
Intervention: Older adults adapting to 1/f noise structure of target-force waveform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young adults adapting to 1/f noise structure of target-force waveform
Number of subjects: 0
Study: 16785755

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 12656658

Group type: EXPERIMENTAL
Intervention: Selenomethionine (Seme) 200 microg plus L-thyroxine (LT(4))
Number of subjects: 65

Group type: COMPARATOR
Intervention: L-thyroxine (LT(4)) plus placebo
Number of subjects: 65
Study: 11152061

Group type: EXPERIMENTAL
Intervention: Herbal dietary supplement containing 10 mg of caffeine and 5 mg of ephedrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 10
Study: 9322173

Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Rubber floor mats
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 8446844

Group type: EXPERIMENTAL
Intervention: Ketotifen, 2 mg twice daily for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketotifen, 2 mg twice daily for 24 hours before indomethacin administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3946946

Group type: EXPERIMENTAL
Intervention: 50 mg doxepin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 100 mg doxepin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30946987

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 29878870

Group type: EXPERIMENTAL
Intervention: 2WALK (sitting with 2-min light-intensity walking breaks every 30 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: SIT (uninterrupted sitting)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 8WALK (sitting with 8-min light-intensity walking breaks every 2 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2WALK
Number of subjects: 15
Study: 27120106

Group type: EXPERIMENTAL
Intervention: Infant formula with 0.3 g/dl GOS (OM55N)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 35
Study: 1428301

Group type: COMPARATOR
Intervention: Midecamycin acetate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Roxithromycin
Number of subjects: 12
Study: 22797673

Group type: EXPERIMENTAL
Intervention: Ferritin concentrations (1-tertile increase)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Overall tertiles of ferritin
Number of subjects: 524
Study: 21129229

Group type: EXPERIMENTAL
Intervention: tinzaparin
Number of subjects: 20

Group type: COMPARATOR
Intervention: UF-heparin
Number of subjects: 20